These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Blood transcriptional signatures of multiple sclerosis: unique gene expression of disease activity. Achiron A; Gurevich M; Friedman N; Kaminski N; Mandel M Ann Neurol; 2004 Mar; 55(3):410-7. PubMed ID: 14991819 [TBL] [Abstract][Full Text] [Related]
26. An extended association screen in multiple sclerosis using 202 microsatellite markers targeting apoptosis-related genes does not reveal new predisposing factors. Gödde R; Brune S; Jagiello P; Sindern E; Haupts M; Schimrigk S; Müller N; Epplen JT J Negat Results Biomed; 2005 Sep; 4():7. PubMed ID: 16143043 [TBL] [Abstract][Full Text] [Related]
27. Recent advances in genetic analysis of multiple sclerosis: genetic associations and therapeutic implications. Niino M; Fukazawa T; Kikuchi S; Sasaki H Expert Rev Neurother; 2007 Sep; 7(9):1175-88. PubMed ID: 17868016 [TBL] [Abstract][Full Text] [Related]
28. Genetic determinants of risk and progression in multiple sclerosis. Didonna A; Oksenberg JR Clin Chim Acta; 2015 Sep; 449():16-22. PubMed ID: 25661088 [TBL] [Abstract][Full Text] [Related]
29. Development of biomarkers for multiple sclerosis as a neurodegenerative disorder. Ziemann U; Wahl M; Hattingen E; Tumani H Prog Neurobiol; 2011 Dec; 95(4):670-85. PubMed ID: 21524682 [TBL] [Abstract][Full Text] [Related]
30. IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations. Weber F; Fontaine B; Cournu-Rebeix I; Kroner A; Knop M; Lutz S; Müller-Sarnowski F; Uhr M; Bettecken T; Kohli M; Ripke S; Ising M; Rieckmann P; Brassat D; Semana G; Babron MC; Mrejen S; Gout C; Lyon-Caen O; Yaouanq J; Edan G; Clanet M; Holsboer F; Clerget-Darpoux F; Müller-Myhsok B Genes Immun; 2008 Apr; 9(3):259-63. PubMed ID: 18354419 [TBL] [Abstract][Full Text] [Related]
31. A null mutation within the ciliary neurotrophic factor (CNTF)-gene: implications for susceptibility and disease severity in patients with multiple sclerosis. Hoffmann V; Pöhlau D; Przuntek H; Epplen JT; Hardt C Genes Immun; 2002 Feb; 3(1):53-5. PubMed ID: 11857064 [TBL] [Abstract][Full Text] [Related]
32. The genetics of multiple sclerosis. Compston A J Neurovirol; 2000 May; 6 Suppl 2():S5-9. PubMed ID: 10871776 [TBL] [Abstract][Full Text] [Related]
33. A new era in the genetic analysis of multiple sclerosis. Sawcer S Curr Opin Neurol; 2006 Jun; 19(3):237-41. PubMed ID: 16702828 [TBL] [Abstract][Full Text] [Related]
34. Fine mapping of multiple sclerosis susceptibility genes provides evidence of allelic heterogeneity at the IL2RA locus. Perera D; Stankovich J; Butzkueven H; Taylor BV; Foote SJ; Kilpatrick TJ; Rubio JP J Neuroimmunol; 2009 Jun; 211(1-2):105-9. PubMed ID: 19375175 [TBL] [Abstract][Full Text] [Related]
35. The multiple sclerosis whole blood mRNA transcriptome and genetic associations indicate dysregulation of specific T cell pathways in pathogenesis. Gandhi KS; McKay FC; Cox M; Riveros C; Armstrong N; Heard RN; Vucic S; Williams DW; Stankovich J; Brown M; Danoy P; Stewart GJ; Broadley S; Moscato P; Lechner-Scott J; Scott RJ; Booth DR; Hum Mol Genet; 2010 Jun; 19(11):2134-43. PubMed ID: 20190274 [TBL] [Abstract][Full Text] [Related]
36. Multiple sclerosis: individualized disease susceptibility and therapy response. Pravica V; Markovic M; Cupic M; Savic E; Popadic D; Drulovic J; Mostarica-Stojkovic M Biomark Med; 2013 Feb; 7(1):59-71. PubMed ID: 23387485 [TBL] [Abstract][Full Text] [Related]
37. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Madsen LS; Andersson EC; Jansson L; krogsgaard M; Andersen CB; Engberg J; Strominger JL; Svejgaard A; Hjorth JP; Holmdahl R; Wucherpfennig KW; Fugger L Nat Genet; 1999 Nov; 23(3):343-7. PubMed ID: 10610182 [TBL] [Abstract][Full Text] [Related]